Worldwide, tens of thousands of people die from melanoma each year, making it the most
frequently fatal form of cutaneous cancer. Immunotherapeutic advancements, particularly …

Immunotherapy has transformed the treatment of advanced melanoma. However, up to two-
thirds of patients experience disease progression after initially achieving a response to …

Optimizing current therapies is among next steps in metastatic melanoma (MM) treatment
landscape. The innovation of this study is the design of production process by microfluidics …

Acral and mucosal melanoma are uncommon variants of melanoma. Acral melanoma has
an age-adjusted incidence of approximately 1.8 cases per million individuals per year …

Acral melanoma (AM) is an aggressive melanoma variant that arises from palmar, plantar,
and nail unit melanocytes. Compared to non-acral cutaneous melanoma (CM), AM is …

Angiogenesis, the expansion of pre-existing vascular networks, is crucial for normal organ
growth and tissue repair, but is also involved in various pathologies, including inflammation …

Melanoma brain metastases present a major challenge in cancer treatment and reduce
overall survival despite advances in managing primary melanoma. Immune checkpoint …

Introduction Increasing evidence from preclinical and clinical studies suggests the role of
vascular endothelial growth factor (VEGF) signaling in melanoma progression, response to …

Background Currently, treatment options for patients with advanced melanoma who
experience failed immunotherapy or targeted therapy are lacking. Recent studies suggest …

Identifying biomarkers to evaluate the therapeutic effect of immune checkpoint inhibitors
(ICIs) is crucial. Regulatory Associated Protein of MTOR Complex 1 (RPTOR), one of the …